AMAG Pharmaceuticals
1100 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 617-498–3300
Fax: 617-499-3361
Website: http://www.amagpharma.com/
Email: contactus@amagpharma.com
About AMAG Pharmaceuticals
Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.
AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.
374 articles about AMAG Pharmaceuticals
-
AMAG Pharmaceuticals, Inc. Receives Fast Track Designation for Ferumoxytol for Vascular-Enhanced Magnetic Resonance Imaging
8/21/2008
-
AMAG Pharmaceuticals, Inc. to Present at the Canaccord Adams 28th Annual Global Growth Conference
8/1/2008
-
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter Ended June 30, 2008
7/29/2008
-
AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2008 to Discuss Financial Results for the Quarter Ended June 30, 2008
7/22/2008
-
AMAG Pharmaceuticals, Inc. Announces Presentation of Positive Results from Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapy in Kidney Transplant Recipients at the American Transplant Congress
6/2/2008
-
AMAG Pharmaceuticals, Inc. to Webcast Upcoming Analyst and Investor Meeting
5/30/2008
-
AMAG Pharmaceuticals, Inc. and 3SBio Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
5/27/2008
-
AMAG Pharmaceuticals, Inc. Announces Appointment of Robert M. Brenner, M.D. as Senior Vice President of Medical Affairs
5/20/2008
-
AMAG Pharmaceuticals, Inc. to Present at the 2008 Citi Global Healthcare Conference
5/13/2008
-
AMAG Pharmaceuticals, Inc. Added to NASDAQ Biotech Index
5/12/2008
-
AMAG Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4/29/2008
-
AMAG Pharmaceuticals, Inc. to Host Conference Call on April 25, 2008 to Discuss Financial Results for the Quarter Ended March 31, 2008
4/21/2008
-
AMAG Pharmaceuticals, Inc. to Present Additional Positive Results from Phase III Studies
4/4/2008
-
AMAG Pharmaceuticals, Inc. to Present at the Cowen and Company 28th Annual Health Care Conference
3/4/2008
-
AMAG Pharmaceuticals, Inc. Announces Addition of Joseph V. Bonventre, M.D., Ph. D. to Board of Directors
2/28/2008
-
AMAG Pharmaceuticals, Inc. Shares Fall Drug Approval Concerns
2/22/2008
-
AMAG Pharmaceuticals, Inc. Reports Financial Results for the Quarter and Year Ended December 31, 2007
2/22/2008
-
AMAG Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Ferumoxytol New Drug Application in Chronic Kidney Disease
2/19/2008
-
AMAG Pharmaceuticals, Inc. to Host Quarterly Earnings Conference Call to Discuss December 31, 2007 Results
2/14/2008
-
AMAG Pharmaceuticals, Inc. Stock Down on Worries That FDA Ruling for Rival Drug Will Hurt Anemia Drug Chances
1/31/2008